Expanded Dose Exploration in Part A and Dose Escalation in Part B of BEAM-302 Phase 1/2 Study in Alpha-1 Antitrypsin ...

Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present updated safety and efficacy data from the BEACON ...

BOOST Pharma ApS, a clinical-stage biopharmaceutical company focused on developing novel cell therapies for rare skeletal pediatric diseases, today announced that Sound Bioventures has joined its ...

The presentation will provide two-year follow-up data from the landmark BOOSTB4 Phase I/II clinical study. Notably, the results demonstrate that more than 50% of the treated patients experienced zero ...

If you’re trying to conceive, learning about fertilisation makes the process less of a mystery. It highlights that conception ...

Only two days after Bridgebio Pharma Inc. impressed investors with data from BBP-418 in limb-girdle muscular dystrophy type 2I/R9, the company was back at it again, this time reporting positive ...

Dyne Therapeutics, Inc. ((DYN)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, ...

The bridge aims to prevent the extinction of local mountain lions by allowing them to breed with other populations.

Beam Therapeutics Inc. trades at a relatively cheap valuation based on its multiples and potential in SCD. Learn more about ...

The 210-foot-long, vegetated bridge is expected to reconnect the Santa Monicas to other areas. In a few weeks, thousands of native plants will be installed on the crossing. Lane closures on Agoura ...

Seven years ago, I took a bet from one of the most controversial figures in the scientific world. Charles Murray, the political scientist who—along with the late psychologist Richard Herrnstein—wrote ...